Evidence map›Paper›PMID 26906034›Full record

Trial reportJournal of cardiovascular pharmacology2016

Interleukin-1 Blockade in Acute Decompensated Heart Failure: A Randomized, Double-Blinded, Placebo-Controlled Pilot Study.

Benjamin W Van Tassell, Nayef A Abouzaki, Claudia Oddi Erdle, Salvatore Carbone, Cory R Trankle, Ryan D Melchior, Jeremy S Turlington, Clinton J Thurber, Sanah Christopher, Dave L Dixon and 7 more

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of cardiovascular pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06286423 (Colchicine in Acutely Decompensated Heart Failure With Reduced Ejection Fraction), which is not on this map. Cited by 76 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 5 pooled it
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06286423 phase4recruitingnot on this mapstarted 2024, after this paper: background citation

Colchicine in Acutely Decompensated Heart Failure With Reduced Ejection Fraction: a Pilot Study

TypeinterventionalSponsorUniversity of VirginiaRan2024 to 2028Enrolled30ConditionsHeart Failure, Decompensated Heart Failure, Heart Failure With Reduced Ejection FractionArmsColchicine 0.6 mg, Control/Placebo group
3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 5 syntheses or guidelines pooled it, 130 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. An integrated overview of acute heart failure: a narrative review of pathophysiological mechanisms and contributing factors.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026
    Review
  11. Review
  12. Article
  13. Anti-inflammatory pharmacotherapy in patients with cardiovascular disease.European heart journal. Cardiovascular pharmacotherapy · 2025
    Review
  14. Review
  15. Immunometabolism in heart failure.Nature reviews. Cardiology · 2025
    Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 2 countries.

Benjamin W Van Tassell*Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, Virginia Commonwealth University, Richmond, VA;†Pauley Heart Center, School of Medicine, Virginia Commonwealth University, Richmond, VA;‡Division of Infectious Diseases, School of Medicine, University of Colorado, Denver, CO;§Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy; and‖Department of AngioCardioNeurology, IRCCS Neuromed, Pozzilli, Italy.
Nayef A Abouzaki
Claudia Oddi Erdle
Salvatore Carbone
Cory R Trankle
Ryan D Melchior
Jeremy S Turlington
Clinton J Thurber
Sanah Christopher
Dave L Dixon
Daniel T Fronk
Christopher S Thomas
Scott W Rose
Leo F Buckley
Charles A Dinarello
Giuseppe Biondi-Zoccai
Antonio Abbate
University of Colorado Denver · USSapienza University of Rome · ITVirginia Commonwealth University · US

Funding

Center for Clinical and Translational ResearchUL1TR000058 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2012 to 2015
$12.5M
Center for Clinical and Translational ResearchKL2TR000057 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2012 to 2014
$1.4M
NCATS NIH HHS KL2 TR000057NCATS NIH HHS UL1 TR000058
6 · The paper itself

Abstract

backgroundHeart failure is an inflammatory disease. Patients with acute decompensated heart failure (ADHF) exhibit significant inflammatory activity on admission. We hypothesized that Interleukin-1 blockade, with anakinra (Kineret, Swedish Orphan Biovitrum), would quench the acute inflammatory response in patients with ADHF.

methodsWe randomized 30 patients with ADHF, reduced left ventricular ejection fraction (<40%), and elevated C reactive protein (CRP) levels (≥5 mg/L) to either anakinra 100 mg twice daily for 3 days followed by once daily for 11 days or matching placebo, in a 1:1 double blinded fashion. We measured daily CRP plasma levels using a high-sensitivity assay during hospitalization and then again at 14 days and evaluated the area-under-the-curve and interval changes (delta).

resultsTreatment with anakinra was well tolerated. At 72 hours, anakinra reduced CRP by 61% versus baseline, compared with a 6% reduction among patients receiving placebo (P = 0.004 anakinra vs. placebo).

conclusionsInterleukin-1 blockade with anakinra reduces the systemic inflammatory response in patients with ADHF. Further studies are warranted to determine whether this anti-inflammatory effect translates into improved clinical outcomes.

Indexed as

Acute DiseaseBiomarkersDouble-Blind MethodFemaleHeart FailureHumansInflammation MediatorsInterleukin-1Interleukin 1 Receptor Antagonist ProteinMaleMiddle AgedPilot ProjectsBiomarkersInflammation MediatorsInterleukin-1Interleukin 1 Receptor Antagonist Protein

Identifiers

PMID26906034
PMCPMC5749643
OpenAlexW2290259186

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.